Factors associated with poor glycemic control in children with type 1 diabetes generally vary according to the insulin regimen used, but family conflict over diabetes management universally impacts all insulin users, US researchers report.
WATCH | Nephrologist Katherine Tuttle and Primary Care Physician Jay Shubrook discuss referrals to nephrology for patients with comorbid diabetes and kidney disease (8:38).
Escalating obesity prevalence and severity has led to type 2 diabetes being diagnosed in ever-younger people, including children. medwireNews rounds up the accumulating evidence suggesting a particularly severe diabetes course in these young people.
Hospitalized individuals with diabetes who have low blood glucose levels on the day of discharge have an elevated risk for readmission and death, findings from a large US cohort study suggest.
Type 2 diabetes remission can be achieved within 1 year at a cost below the average annual cost of diabetes management, even when including complications, shows an economic evaluation of the DiRECT/Counterweight-Plus weight management program.
Rates of age-standardized all-cause mortality due to diabetes as the underlying or contributing cause of death have plateaued in recent years following earlier declines, shows an analysis of data from the US Census and national mortality database.
Research shows that being diagnosed with type 1 diabetes after the age of 30 years is relatively common, yet people are often misdiagnosed with type 2 diabetes, despite rapid progression to insulin dependence.
Factors associated with poor glycemic control in children with type 1 diabetes generally vary according to the insulin regimen used, but family conflict over diabetes management universally impacts all insulin users, US researchers report.
Delivery of bolus insulin via a patch results in similar glycemic control to that delivered by a conventional pen, with improvements in treatment satisfaction and quality of life, findings from a randomized trial suggest.
Fournier gangrene remains very rare, but is more common in people using SGLT2 inhibitors compared with other diabetes medications and has severe consequences, shows research.
What does the proliferation of diabetes self-management and monitoring technologies in pediatric care mean for the future of adult services? Katharine Barnard looks at the situation in England and Wales.
The Ellipse investigators report improved glycemic control at the price of early and mostly mild gastrointestinal events in children and adolescents with type 2 diabetes.
Lead investigator Vlado Perkovic talks about the main findings from the CREDENCE trial – demonstrating that canagliflozin is associated with a reduced risk for kidney failure and cardiovascular events in people with type 2 diabetes and chronic kidney disease – and discusses how these results will impact clinical practice (6:51).
Editorial Board member Lori Berard discusses how the ambulatory glucose profile is quietly revolutionizing the analysis of blood glucose and glycemic control for patients and practitioners.
